$BOTH
BIOETHICS LTD

2024 Q4 Form 10-Q Financial Statement

#000147793224007440 Filed on November 19, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $39.28K
YoY Change 292.68%
Operating Profit -$39.28K
YoY Change 292.68%
Interest Expense $13.80K
YoY Change 12.22%
% of Operating Profit
Other Income/Expense, Net -$13.80K
YoY Change 12.22%
Pretax Income -$53.08K
YoY Change 138.04%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$53.08K
YoY Change 138.04%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 1.135M shares 1.135M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $17.15K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $17.15K
YoY Change 3451.35%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $17.15K
Total Long-Term Assets $0.00
Total Assets $17.15K
YoY Change 3451.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $177.2K
YoY Change 52.1%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $880.1K
YoY Change 16.98%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $880.1K
Total Long-Term Liabilities
Total Liabilities $880.1K
YoY Change 16.98%
SHAREHOLDERS EQUITY
Retained Earnings -$1.407M
YoY Change 12.21%
Common Stock $1.135K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$862.9K
YoY Change
Total Liabilities & Shareholders Equity $17.15K
YoY Change 3451.35%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$53.08K
YoY Change 138.04%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
620000 shares
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135194 shares
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1406547 usd
us-gaap Net Income Loss
NetIncomeLoss
-128668 usd
us-gaap Net Income Loss
NetIncomeLoss
-72746 usd
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
dei Entity Central Index Key
EntityCentralIndexKey
0000894560
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
620000 shares
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135194 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135194 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1135194 shares
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
33-55254-41
dei Entity Registrant Name
EntityRegistrantName
BIOETHICS, LTD.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
87-0485312
dei Entity Address Address Line1
EntityAddressAddressLine1
1661 Lakeview Circle
dei Entity Address City Or Town
EntityAddressCityOrTown
Ogden
dei Entity Address State Or Province
EntityAddressStateOrProvince
UT
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
84403
dei City Area Code
CityAreaCode
801
dei Local Phone Number
LocalPhoneNumber
399-3632
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
true
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1135194 shares
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17153 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
138 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
17153 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
138 usd
CY2024Q3 us-gaap Assets
Assets
17153 usd
CY2023Q4 us-gaap Assets
Assets
138 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
177193 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
122400 usd
CY2024Q3 both Accounts Payables Related Parties Current
AccountsPayablesRelatedPartiesCurrent
1000 usd
CY2023Q4 both Accounts Payables Related Parties Current
AccountsPayablesRelatedPartiesCurrent
14500 usd
CY2024Q3 both Accrued Interest Related Parties
AccruedInterestRelatedParties
91183 usd
CY2023Q4 both Accrued Interest Related Parties
AccruedInterestRelatedParties
98406 usd
CY2024Q3 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
114771 usd
CY2023Q4 us-gaap Deposit Liabilities Accrued Interest
DepositLiabilitiesAccruedInterest
98363 usd
CY2024Q3 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
35000 usd
CY2023Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
35000 usd
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
190000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
160000 usd
CY2024Q3 both Notes Payable Related Parties
NotesPayableRelatedParties
270939 usd
CY2023Q4 both Notes Payable Related Parties
NotesPayableRelatedParties
247734 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
880086 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
776403 usd
CY2024Q3 us-gaap Liabilities
Liabilities
880086 usd
CY2023Q4 us-gaap Liabilities
Liabilities
776403 usd
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
6200 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1135194 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
1135 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1135 usd
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
556279 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
500479 usd
CY2024Q3 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
20000 usd
CY2023Q4 us-gaap Common Stock Share Subscribed But Unissued Subscriptions Receivable
CommonStockShareSubscribedButUnissuedSubscriptionsReceivable
0 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1406547 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1277879 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-862933 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-776265 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
17153 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
138 usd
CY2024Q3 us-gaap Revenues
Revenues
0 usd
CY2023Q3 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
39284 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10004 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
89483 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
36843 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
39284 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
10004 usd
us-gaap Operating Expenses
OperatingExpenses
89483 usd
us-gaap Operating Expenses
OperatingExpenses
36843 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-39284 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10004 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-89483 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-36843 usd
CY2024Q3 us-gaap Interest Expense
InterestExpense
13799 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
12296 usd
us-gaap Interest Expense
InterestExpense
39185 usd
us-gaap Interest Expense
InterestExpense
35903 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-13799 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12296 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-39185 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-35903 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53083 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22300 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-128668 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72746 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-53083 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22300 usd
us-gaap Net Income Loss
NetIncomeLoss
-128668 usd
us-gaap Net Income Loss
NetIncomeLoss
-72746 usd
CY2024Q3 both Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.05
CY2023Q3 both Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.02
both Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.11
both Basic And Diluted Loss Per Share
BasicAndDilutedLossPerShare
-0.06
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1135194 shares
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-776265 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-39653 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-815918 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-35932 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-851850 usd
CY2024Q3 both Preferred Stock Issued For Cash Amount
PreferredStockIssuedForCashAmount
42000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-53083 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-862933 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-679116 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-23636 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-702752 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-26810 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-729562 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-22300 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-751862 usd
us-gaap Profit Loss
ProfitLoss
128668 usd
us-gaap Profit Loss
ProfitLoss
72746 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
54793 usd
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
16231 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-13500 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
4500 usd
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
-7223 usd
us-gaap Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
20346 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
16408 usd
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
15557 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-78190 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-16112 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 usd
us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
42000 usd
us-gaap Proceeds From Issuance Of Redeemable Preferred Stock
ProceedsFromIssuanceOfRedeemablePreferredStock
0 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
30000 usd
us-gaap Proceeds From Repayments Of Related Party Debt
ProceedsFromRepaymentsOfRelatedPartyDebt
0 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
23205 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
16300 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
95205 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16300 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
17015 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
188 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
138 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
295 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17153 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
483 usd
us-gaap Interest Paid Net
InterestPaidNet
5000 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
both Preferred Stock Subscription Receivable
PreferredStockSubscriptionReceivable
20000 usd
both Preferred Stock Subscription Receivable
PreferredStockSubscriptionReceivable
0 usd
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
25000000 shares
both Basic And Diluted Losses Per Share
BasicAndDilutedLossesPerShare
-0.11
both Basic And Diluted Losses Per Share
BasicAndDilutedLossesPerShare
-0.06
both Conetible Debt Conversion In Common Stock
ConetibleDebtConversionInCommonStock
15596 shares
both Conetible Debt Conversion In Common Stock
ConetibleDebtConversionInCommonStock
15281 shares

Files In Submission

Name View Source Status
0001477932-24-007440-index-headers.html Edgar Link pending
0001477932-24-007440-index.html Edgar Link pending
0001477932-24-007440.txt Edgar Link pending
0001477932-24-007440-xbrl.zip Edgar Link pending
both-20240930.xsd Edgar Link pending
both_10q.htm Edgar Link pending
both_ex311.htm Edgar Link pending
both_ex321.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
both-20240930_cal.xml Edgar Link unprocessable
both-20240930_def.xml Edgar Link unprocessable
both-20240930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
both-20240930_pre.xml Edgar Link unprocessable
both_10q_htm.xml Edgar Link completed